Exposure to Cypress Pollens and Subsequent Symptoms: A Panel Study.


Journal

International archives of allergy and immunology
ISSN: 1423-0097
Titre abrégé: Int Arch Allergy Immunol
Pays: Switzerland
ID NLM: 9211652

Informations de publication

Date de publication:
2019
Historique:
received: 25 03 2019
accepted: 28 05 2019
pubmed: 8 8 2019
medline: 5 11 2019
entrez: 8 8 2019
Statut: ppublish

Résumé

The objective of this panel study was to document the relationship between exposure to cypress pollen and allergic symptoms. The study group included 47 patients with allergy to cypress pollen who completed a daily diary and a weekly evaluation of quality of life (QoL) during the cypress pollen season. Different patients were included in three consecutive pollen seasons: 2014-2015, 2015-2016, and 2016-2017. Daily cypress pollen counts were obtained from the National Aerobiological Network. Air pollution and meteorological data were recorded on a daily basis. The pollen-symptoms relationship was quantified by calculating odds ratios for an increase of 1 log of grains of pollen/m3, taking into account potential confounding factors. The QoL score was expressed with a beta coefficient that increased with 1 grain of pollen/m3. There was a marked increase in rhinitis and ocular symptoms during the pollen season, with a plateau effect at high levels of exposure, but no relationship with bronchial symptoms. The QoL score had a linear and significant relationship with the cypress pollen count. We did not detect any threshold level. This panel study demonstrated a significant association between exposure to cypress pollens and allergic symptoms, with a plateau effect for high exposures.

Identifiants

pubmed: 31390631
pii: 000501223
doi: 10.1159/000501223
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-141

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Thierry Rakotozandry (T)

Pulmonology Department, Marseille Public University Hospital System, Marseille, France.

Etienne Cassagne (E)

SEPIA-Santé, Baud, France.

Sylvie Martin (S)

SEPIA-Santé, Baud, France.

Pierre Alauzet (P)

Pulmonology Department, Marseille Public University Hospital System, Marseille, France.

Ingrid Navarro (I)

Pulmonology Department, Marseille Public University Hospital System, Marseille, France.

Clémentine Delcroux (C)

Pulmonology Department, Marseille Public University Hospital System, Marseille, France.

Denis Caillaud (D)

Montpied Hospital, CHU of Clermont-Ferrand, Clermont-Ferrand, France.

Jean-Pierre Besancenot (JP)

National Aerobiological Network, Brussieu, France.

Michel Thibaudon (M)

National Aerobiological Network, Brussieu, France.

Denis Charpin (D)

Pulmonology Department, Marseille Public University Hospital System, Marseille, France, denis-andre.charpin@ap-hm.fr.
Aix-Marseille University, Marseille, France, denis-andre.charpin@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH